Related Experiment Videos
Emergence of low-molecular-weight heparins in cardiology
1Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
Insights
New antithrombotic agents, such as low-molecular-weight heparins, are expanding drug therapy for acute coronary syndromes. This review discusses their epidemiology, pathophysiology, and historical use in treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) represent a significant cardiovascular disease burden.
- Antithrombotic therapy is a cornerstone in managing ACS.
- Recent advancements have introduced novel antithrombotic agents.
Purpose of the Study:
- To review the evolving landscape of drug therapy for ACS.
- To highlight the role of new antithrombotic agents, including low-molecular-weight heparins.
- To provide historical context for antithrombotic treatment in ACS.
Main Methods:
- Literature review of recent advancements in ACS pharmacotherapy.
- Discussion of epidemiological and pathophysiological aspects of ACS.
- Historical analysis of antithrombotic therapy evolution.
Main Results:
- The field of ACS drug therapy is rapidly advancing.
- Low-molecular-weight heparins are among the new antithrombotic agents introduced.
- The review covers epidemiology, pathophysiology, and historical treatment perspectives.
Conclusions:
- Novel antithrombotic agents are expanding treatment options for ACS.
- Understanding the historical context is crucial for appreciating current therapeutic strategies.
- Continued research is vital for optimizing ACS management.
Abstract:
Drug therapy for the management of acute coronary syndromes is rapidly expanding. Over the past few years, a number of new antithrombotic agents have been introduced, including low-molecular-weight heparins. The epidemiology and pathophysiology of acute coronary syndromes are discussed, with a historical perspective on the use of antithrombotic therapy.